Please login to the form below

Not currently logged in
Email:
Password:

Fampyra

This page shows the latest Fampyra news and features for those working in and with pharma, biotech and healthcare.

NICE denies two drugs in new MS guidance

NICE denies two drugs in new MS guidance

NICE denies two drugs in new MS guidance. Sativex and Fampyra too costly for NHS in England. ... Michelle Mitchell, chief executive of the MS Society, said: “ NICE's decision to reject Sativex and Fampyra as treatment options is really disappointing.

Latest news

  • FDA approves Biogen Idec's long-acting MS therapy FDA approves Biogen Idec's long-acting MS therapy

    Plegridy is Biogen Idec's fifth MS treatment to reach the market joining Avonex, Tysabri (natalizumab), fast-growing oral therapy Tecfidera (dimethyl fumarate) and Fampyra (fampridine).

  • IQWiG backs BMS' Yervoy for melanoma IQWiG backs BMS' Yervoy for melanoma

    delivered a negative appraisal for Biogen Idec's multiple sclerosis drug Fampyra (prolonged-release fampridine).

  • IQWiG turns down GSK’s lupus drug Benlysta IQWiG turns down GSK’s lupus drug Benlysta

    IQWiG turns down GSK’ s lupus drug Benlysta. German HTA body also declines to back Biogen Idec’ s Fampyra in its draft assessments. ... Further no from IGWiG for Biogen Idec's Fampyra. In addition to its Benlysta guidance, IQWiG also released a draft

  • Avonex slowdown hits Biogen Idec in first quarter Avonex slowdown hits Biogen Idec in first quarter

    Fampyra  (prolonged-release fampridine) for improving walking ability in MS patients made a solid start with $15m in revenues in the quarter following launches in Germany, the UK, Australia, Denmark, Norway,

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SpotMe

SpotMe is the leading technology and service provider of enterprise engagement platforms with a focus on live events, virtual and...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics